Mori A - Search Results

1

Radiation treatment plus CCNU plus the radiosensitizer lonidamine in malignant gliomas operated.

Guglielmi A, Bruzzone E, Gentile SL, Barra S, Mori A, Bacigalupo A, Rosso R, Vitale V, Giaretti W, Frosina G, et al. Guglielmi A, et al. Among authors: mori a. Anticancer Res. 1991 Sep-Oct;11(5):1779-82. Anticancer Res. 1991. PMID: 1662925

2

[Cell resistance in oncology. Therapeutic prospects].

Rosso R, Guglielmi A, Aschele C, Mori A, Tixi L, Bolli E, Sobrero A. Rosso R, et al. Among authors: mori a. G Ital Chemioter. 1991 Jan-Dec;38(1-3):95-7. G Ital Chemioter. 1991. PMID: 1365622 Italian. No abstract available.

3

Schedule-selective biochemical modulation of 5-fluorouracil: a phase II study in advanced colorectal cancer.

Sobrero AF, Aschele C, Guglielmi AP, Mori AM, Tixi LM, Bolli EA, Rosso R, Mammoliti S, Rollandi GA, Bertoglio S, et al. Sobrero AF, et al. Among authors: mori am. Clin Cancer Res. 1995 Sep;1(9):955-60. Clin Cancer Res. 1995. PMID: 9816066 Clinical Trial.

4

5-Fluorouracil plus 5-methyltetrahydrofolate in advanced pancreatic cancer. GLISP (Gruppo Ligure Studio Pancreas).

Bolli E, Saccomanno S, Mondini G, Aschele C, Guglielmi A, Ligas B, Connio M, Mori A, Rosso R, Sobrero A, et al. Bolli E, et al. Among authors: mori a. Cancer Chemother Pharmacol. 1995;35(4):339-42. doi: 10.1007/BF00689455. Cancer Chemother Pharmacol. 1995. PMID: 7828278 Clinical Trial.

5

Activity of continuous-infusion 5-fluorouracil in patients with advanced colorectal cancer clinically resistant to bolus 5-fluorouracil.

Mori A, Bertoglio S, Guglielmi A, Aschele C, Bolli E, Tixi L, Rosso R, Sobrero A. Mori A, et al. Cancer Chemother Pharmacol. 1993;33(2):179-80. doi: 10.1007/BF00685339. Cancer Chemother Pharmacol. 1993. PMID: 8261580

6

Adjuvant Treatment of Colorectal Cancer in the Elderly.

Aschele C, Guglielmi A, Tixi LM, Bolli E, Mori AM, Lionetto R, Rosso R, Sobrero A. Aschele C, et al. Among authors: mori am. Cancer Control. 1995 Mar;2(2 Suppl 1):36-38. Cancer Control. 1995. PMID: 10887408

7

Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells.

Sobrero AF, Aschele C, Guglielmi AP, Mori AM, Melioli GG, Rosso R, Bertino JR. Sobrero AF, et al. Among authors: mori am. J Natl Cancer Inst. 1993 Dec 1;85(23):1937-44. doi: 10.1093/jnci/85.23.1937. J Natl Cancer Inst. 1993. PMID: 8230285

8

Phase II study of 5-fluorouracil plus leucovorin and interferon alpha 2b in advanced colorectal cancer.

Sobrero A, Nobile MT, Guglielmi A, Mori A, Aschele C, Bolli E, Tixi L, Gallo L, Parodi GC, Bruzzi P, et al. Sobrero A, et al. Among authors: mori a. Eur J Cancer. 1992;28A(4-5):850-2. doi: 10.1016/0959-8049(92)90130-t. Eur J Cancer. 1992. PMID: 1524906 Clinical Trial.

9

In vitro synergism between 5-fluorouracil and natural beta interferon in human colon carcinoma cells.

Guglielmi A, Aschele C, Mori A, Baldo C, Russo P, Debernardis D, Valenti M, Bruno S, Taverna M, Rosso R, et al. Guglielmi A, et al. Among authors: mori a. Clin Cancer Res. 1995 Nov;1(11):1337-44. Clin Cancer Res. 1995. PMID: 9815929

10

Standard indication of immunotherapy for the treatment of cancer.

Bolli E, Tixi L, Mori A, Guglielmi A, Aschele C, Rovini E, Sobrero A. Bolli E, et al. Among authors: mori a. Pharmacol Res. 1992 Sep;26 Suppl 2:100-1. doi: 10.1016/1043-6618(92)90617-k. Pharmacol Res. 1992. PMID: 1384019 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,606 results

Search Page

Filters